NASDAQ:IMRX Immuneering (IMRX) Stock Price, News & Analysis $1.43 -0.03 (-2.05%) As of 02:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Immuneering Stock (NASDAQ:IMRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immuneering alerts:Sign Up Key Stats Today's Range$1.43▼$1.4950-Day Range$1.24▼$1.8452-Week Range$1.00▼$3.83Volume39,848 shsAverage Volume2.34 million shsMarket Capitalization$51.32 millionP/E RatioN/ADividend YieldN/APrice Target$12.50Consensus RatingHold Company OverviewImmuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Read More… Immuneering Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreIMRX MarketRank™: Immuneering scored higher than 72% of companies evaluated by MarketBeat, and ranked 291st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingImmuneering has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageImmuneering has only been the subject of 2 research reports in the past 90 days.Read more about Immuneering's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Immuneering are expected to grow in the coming year, from ($1.86) to ($1.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immuneering is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immuneering is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmuneering has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Immuneering's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.13% of the float of Immuneering has been sold short.Short Interest Ratio / Days to CoverImmuneering has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immuneering has recently decreased by 24.65%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmuneering does not currently pay a dividend.Dividend GrowthImmuneering does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.13% of the float of Immuneering has been sold short.Short Interest Ratio / Days to CoverImmuneering has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immuneering has recently decreased by 24.65%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News SentimentN/A News SentimentImmuneering has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.MarketBeat Follows1 people have added Immuneering to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immuneering insiders have not sold or bought any company stock.Percentage Held by Insiders25.00% of the stock of Immuneering is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.65% of the stock of Immuneering is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immuneering's insider trading history. Receive IMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter. Email Address IMRX Stock News HeadlinesImmuneering to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comImmuneering Corporation: Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 21, 2025 | finanznachrichten.deTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 25, 2025 | Porter & Company (Ad)Immuneering Corporation Announces Grant of Inducement AwardMarch 21, 2025 | globenewswire.comImmuneering Corporation: Immuneering Names Dr. Igor Matushansky as Chief Medical OfficerMarch 21, 2025 | finanznachrichten.deImmuneering appoints Matushansky as Chief Medical OfficerMarch 21, 2025 | markets.businessinsider.comImmuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 20, 2025 | globenewswire.comImmuneering Names Dr. Igor Matushansky as Chief Medical OfficerMarch 20, 2025 | globenewswire.comSee More Headlines IMRX Stock Analysis - Frequently Asked Questions How have IMRX shares performed this year? Immuneering's stock was trading at $2.20 on January 1st, 2025. Since then, IMRX shares have decreased by 35.0% and is now trading at $1.43. View the best growth stocks for 2025 here. How were Immuneering's earnings last quarter? Immuneering Co. (NASDAQ:IMRX) issued its quarterly earnings results on Thursday, March, 20th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.16. When did Immuneering IPO? Immuneering (IMRX) raised $105 million in an initial public offering on Friday, July 30th 2021. The company issued 7,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities served as the underwriters for the IPO. How do I buy shares of Immuneering? Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immuneering own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immuneering investors own include Tesla (TSLA), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Advanced Micro Devices (AMD), Meta Platforms (META) and Home Depot (HD). Company Calendar Last Earnings3/20/2025Today4/25/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMRX CIK1790340 Webwww.immuneering.com Phone617-500-8080FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$12.50 High Stock Price Target$13.00 Low Stock Price Target$12.00 Potential Upside/Downside+774.1%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-79.19% Return on Assets-69.08% Debt Debt-to-Equity RatioN/A Current Ratio7.99 Quick Ratio7.99 Sales & Book Value Annual Sales$320,000.00 Price / Sales160.37 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book0.46Miscellaneous Outstanding Shares35,887,000Free Float23,288,000Market Cap$51.32 million OptionableNot Optionable Beta-0.25 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:IMRX) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.